These findings strongly support the interpretation that 4-week DDDF-induced CD248 upregulation in subjects with metabolic syndrome and MASLD may represent an immune-regulatory response, contributing to the suppression of HepG2 liver cancer cell proliferation observed in our study. This evidence concerns the gene CD248 and metabolic syndrome.